Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer

Abstract

Immune checkpoint inhibitors (ICIs) are gradually replacing chemotherapy as the cornerstone of the treatment of advanced malignant tumors because of their long-lasting and significant effect in different tumor types and greatly prolonging the survival time of patients. However, not all patients can respond to ICIs, and even rapid tumor growth after treatment with ICI has been observed in a number of clinical studies. This rapid progression phenomenon is called hyper-progressive disease (HPD). The occurrence of HPD is not uncommon. Past statistics show that the incidence of HPD is 4%-29% in different tumor types, and the progression-free survival and overall survival of patients with HPD are significantly shorter than those of the non-HPD progressor group. With the deepening of the study of HPD, we have established a preliminary understanding of HPD, but the diagnostic criteria of HPD are still not unified, and the addition of biomarkers may break this dilemma. In addition, quite a few immune cells have been found to be involved in the occurrence and development of HPD in the tumor microenvironment, indicating that the molecular mechanism of HPD may be triggered by a variety of ongoing events at the same time. In this review, we summarize past findings, including case reports, clinical trials, and fundamental research; compare the diagnostic criteria, incidence, and clinical prognostic indicators of HPD in different studies; and explore the molecular mechanism and future research direction of HPD.

Keywords

Immune checkpoint inhibitors / hyper-progressive disease / immunotherapy / tumor microenvironment

References

[1] Lahmar J,Koscielny S.Immune checkpoint inhibitors (IC) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC).Ann Oncol2016;27:vi423

[2] Champiat S,Ammari S.Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1.Clin Cancer Res2017;23:1920-8

[3] Socinski M,Horn L.NSCLC, metastatic CheckMate 026: a phase 3 trial of nivolumab vs investigator’s choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC.Ann Oncol2016;27:vi577

[4] Peters S,Horn L.OA03.05 analysis of early survival in patients with advanced non-squamous NSCLC treated with nivolumab vs docetaxel in CheckMate 057.J Thorac Oncol2017;12:S253

[5] Reck M,Lee KH.Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.Eur J Cancer2019;116:137-47

[6] Ferris RL,Fayette J.Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.Oral Oncol2018;81:45-51 PMCID:PMC6563923

[7] Fradet Y,Vaughn DJ.Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.Ann Oncol2019;30:970-6 PMCID:PMC6594457

[8] Powles T,van der Heijden MS.Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.Lancet2018;391:748-57

[9] Ferrara R,Texier M.Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy.JAMA Oncol2018;4:1543-52 PMCID:PMC6248085

[10] Mellema WW,Smit EF.Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case report.Lung Cancer2015;87:201-3

[11] Aoki M,Nagashima K.Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer.ESMO Open2019;4:e000488 PMCID:PMC6555603

[12] Kato S,Walavalkar V,Sharabi A.Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate.Clin Cancer Res2017;23:4242-50 PMCID:PMC5647162

[13] Saâda-Bouzid E,Karabajakian A.Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.Ann Oncol2017;28:1605-11

[14] Kim Y,Lee HY.Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced non-small cell lung cancer treated with immune checkpoint inhibitor.J Thorac Oncol2019;14:1608-18

[15] Kas B,Ferrara R.Clarification of definitions of hyperprogressive disease during immunotherapy for non-small cell lung cancer.JAMA Oncol2020;6:1039-46 PMCID:PMC7290708

[16] Matos I,Hierro C.Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials.JCO2018;36:3032

[17] Matos I,García-Ruiz A.Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria.Clin Cancer Res2020;26:1846-55

[18] Gomes da Morais AL, de Miguel M, Cardenas JM, Calvo E. Comparison of radiological criteria for hyperprogressive disease in response to immunotherapy.Cancer Treat Rev2020;91:102116

[19] Abbar B,Gougis P.Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.Lung Cancer2021;152:109-18

[20] Chen S,Yan H.Hyperprogressive disease caused by PD-1 inhibitors for the treatment of pan-cancer.Dis Markers2021;2021:6639366 PMCID:PMC8241516

[21] Kim JY,Kang J.Hyperprogressive disease during anti-PD-1 (PDCD1) / PD-L1 (CD274) therapy: a systematic review and meta-analysis.Cancers (Basel)2019;11:1699 PMCID:PMC6896059

[22] Park HJ,Won SE.Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis.JAMA Netw Open2021;4:e211136 PMCID:PMC7991969

[23] Kim CG,Pyo KH.Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.Ann Oncol2019;30:1104-13

[24] Kim SH,Lee DH.Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.J Cancer Res Clin Oncol2020;146:3025-36

[25] Kang DH,Sun P.Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors.Cancer Immunol Immunother2021;

[26] Chen Y,Bu F,Fei K.Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis.BMC Cancer2020;20:707 PMCID:PMC7392646

[27] Chubachi S,Irie H.A case of non-small cell lung cancer with possible “disease flare” on nivolumab treatment.Case Rep Oncol Med2016;2016:1075641 PMCID:PMC5223009

[28] Bernal Vaca L, Mendoza SD, Vergel JC, Rueda X, Bruges R. Hyperprogression in pediatric melanoma metastatic to the breast treated with a checkpoint inhibitor.Cureus2019;11:e3859

[29] Kanazu M,Krebe H.Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: a case series.Thorac Cancer2018;9:1782-7 PMCID:PMC6275832

[30] Liu C,Shang Z.Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature.BMC Urol2021;21:42 PMCID:PMC7981866

[31] Park JH,Lee YG.Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.J Cancer Res Clin Oncol2020;146:3359-69

[32] Xu Z,Zheng L.Hyperprogressive disease in cervical small cell carcinoma treated by immune checkpoint inhibitor.Onco Targets Ther2019;12:8873-7 PMCID:PMC6826182

[33] Sun D,Liu Q.Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma.Cancer Biol Ther2020;21:1097-104 PMCID:PMC7722699

[34] Barham W,Park SS,Dong H.Case report: simultaneous hyperprogression and fulminant myocarditis in a patient with advanced melanoma following treatment with immune checkpoint inhibitor therapy.Front Immunol2020;11:561083 PMCID:PMC7884751

[35] Yang N,Liu ZJ.Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy: a case report.Medicine (Baltimore)2020;99:e22933 PMCID:PMC7598810

[36] Peng Y,Zeng T.Characterization of hyperprogression after immunotherapy in a lung adenocarcinoma patient with strong expression of programmed death ligand 1.J Thorac Oncol2020;15:e4-8

[37] Feng D,Liu M.Excellent response to atezolizumab after clinically defined hyperprogression upon previous treatment with pembrolizumab in metastatic triple-negative breast cancer: a case report and review of the literature.Front Immunol2021;12:608292 PMCID:PMC8201609

[38] Sama S,Lopetegui Lia N.Hyperprogression in PDL1 expressive, recurrent gastroesophageal-junction adenocarcinoma after pembrolizumab.Cureus2019;11:e4862 PMCID:PMC6684307

[39] Iwai Y,Chamoto K.Cancer immunotherapies targeting the PD-1 signaling pathway.J Biomed Sci2017;24:26 PMCID:PMC5381059

[40] Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer2012;12:252-64 PMCID:PMC4856023

[41] Keir ME,Freeman GJ.PD-1 and its ligands in tolerance and immunity.Annu Rev Immunol2008;26:677-704

[42] Marcucci F.The tumor-promoting effects of the adaptive immune system: a cause of hyperprogressive disease in cancer?.Cell Mol Life Sci2021;78:853-65

[43] Kmieciak M,Dumur CI.HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.Eur J Immunol2007;37:675-85 PMCID:PMC3732067

[44] Facoetti A,Zelini P.Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.Clin Cancer Res2005;11:8304-11

[45] Marcucci F,Corti A.Tumor cell-associated immune checkpoint molecules - drivers of malignancy and stemness.Biochim Biophys Acta Rev Cancer2017;1868:571-83

[46] Breunig C,Küblbeck M.MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells.Cell Death Dis2017;8:e2973 PMCID:PMC5596553

[47] Noh KH,Kim JH.API5 confers tumoral immune escape through FGF2-dependent cell survival pathway.Cancer Res2014;74:3556-66 PMCID:PMC4394897

[48] Brenner E,Ahmetlić F.Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours.Nat Commun2020;11:1335 PMCID:PMC7067802

[49] Romeo E,Rumio C.The vicious cross-talk between tumor cells with an EMT phenotype and cells of the immune system.Cells2019;8:460 PMCID:PMC6562673

[50] Singavi A,Kilari D.Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) - analysis of somatic alterations (SAs).Ann Oncol2017;28:v405

[51] Economopoulou P,Papaxoinis G.Patterns of response to immune checkpoint inhibitors in association with genomic and clinical features in patients with head and neck squamous cell carcinoma (HNSCC).Cancers (Basel)2021;13:286 PMCID:PMC7828787

[52] Zhao K,Zhang G.Regulation of the Mdm2-p53 pathway by the ubiquitin E3 ligase MARCH7.EMBO Rep2018;19:305-19 PMCID:PMC5797962

[53] Kato S,Gay L.Analysis of MDM2 amplification: next-generation sequencing of patients with diverse malignancies.JCO Precis Oncol2018;2018 PMCID:PMC6106866

[54] Fang DD,Kong Y.MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.J Immunother Cancer2019;7:327 PMCID:PMC6883539

[55] Sahin I,Navaraj A.AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.Cell Death Discov2020;6:57 PMCID:PMC7338458

[56] Montesinos P,Catalani O.MIRROS: a randomized, placebo-controlled, phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia.Future Oncol2020;16:807-15 PMCID:PMC7338458

[57] Konopleva M,Daver N.MDM2 inhibition: an important step forward in cancer therapy.Leukemia2020;34:2858-74

[58] Sun L,Yu J.Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis.Sci Rep2020;10:2083 PMCID:PMC7005709

[59] Sugiyama E,Takeuchi Y.Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer.Sci Immunol2020;5:eaav3937

[60] Akbay EA,Carretero J.Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.Cancer Discov2013;3:1355-63 PMCID:PMC3864135

[61] Xiong D,Singavi AK,George B.Immunogenomic landscape contributes to hyperprogressive disease after anti-PD-1 immunotherapy for cancer.iScience2018;9:258-77 PMCID:PMC6234258

[62] Tay C,Sakaguchi S.Hyper-progressive disease: the potential role and consequences of T-regulatory cells foiling anti-PD-1 cancer immunotherapy.Cancers (Basel)2020;13:48 PMCID:PMC7796137

[63] Gallimore A,Roychoudhuri R.Regulatory T cells in cancer: where are we now?.Immunology2019;157:187-9 PMCID:PMC6587319

[64] Kamada T,Tay C.PD-1⁺ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.Proc Natl Acad Sci U S A2019;116:9999-10008 PMCID:PMC6525547

[65] Shang B,Jiang SJ.Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis.Sci Rep2015;5:15179 PMCID:PMC4604472

[66] Ono M,Ohkura N.Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1.Nature2007;446:685-9

[67] Wu Y,Heissmeyer V.FOXP3 controls regulatory T cell function through cooperation with NFAT.Cell2006;126:375-87

[68] Sawant DV,Chikina M.Adaptive plasticity of IL-10⁺ and IL-35⁺ T_reg cells cooperatively promotes tumor T cell exhaustion.Nat Immunol2019;20:724-35 PMCID:PMC6531353

[69] Turnis ME,Szymczak-Workman AL.Interleukin-35 limits anti-tumor immunity.Immunity2016;44:316-29 PMCID:PMC4758699

[70] Lin JT,Xia L.TGF-beta 1 uses distinct mechanisms to inhibit IFN-gamma expression in CD4+ T cells at priming and at recall: differential involvement of Stat4 and T-bet.J Immunol2005;174:5950-8

[71] Ring S,Schild H.Regulatory T cell-derived adenosine induces dendritic cell migration through the Epac-Rap1 pathway.J Immunol2015;194:3735-44

[72] Onishi Y,Yamaguchi T.Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation.Proc Natl Acad Sci U S A2008;105:10113-8 PMCID:PMC2481354

[73] Qureshi OS,Nakamura K.Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.Science2011;332:600-3 PMCID:PMC3198051

[74] Gavin MA,Fontenot JD.Foxp3-dependent programme of regulatory T-cell differentiation.Nature2007;445:771-5

[75] Boross P,Martin-Ramirez J.The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility.J Immunol2011;187:1304-13

[76] Murakami T,Takamatsu K.Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma.Cancer Immunol Immunother2021;70:3001-13

[77] Arce Vargas F, Furness AJS, Solomon I, et al; Melanoma TRACERx Consortium, Renal TRACERx Consortium, Lung TRACERx Consortium. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors.Immunity2017;46:577-86 PMCID:PMC5437702

[78] Boisgerault N,Pulido J.Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.Mol Ther2013;21:1507-16 PMCID:PMC3734666

[79] Matsushita H,Koboldt DC.Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.Nature2012;482:400-4 PMCID:PMC3874809

[80] Asgarova A,Godet Y.PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma.Oncoimmunology2018;7:e1423170 PMCID:PMC5927541

[81] Prestipino A.Clinical implications of tumor-intrinsic mechanisms regulating PD-L1.Sci Transl Med2019;11:eaav4810

[82] Terry S,Tan TZ.Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: consequences on susceptibility to cell-mediated cytotoxicity.Oncoimmunology2017;6:e1271858 PMCID:PMC5353930

[83] Terry S,Ortiz-Cuaran S.New insights into the role of EMT in tumor immune escape.Mol Oncol2017;11:824-46 PMCID:PMC5496499

[84] Benci JL,Qiu Y.Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade.Cell2016;167:1540-54.e12 PMCID:PMC5385895

[85] Minn AJ.Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling.Cell2016;165:272-5

[86] Zhang Y,Riquelme E.Immune cell production of interleukin 17 induces stem cell features of pancreatic intraepithelial neoplasia cells.Gastroenterology2018;155:210-23.e3 PMCID:PMC6035075

[87] Guo N,Zhang Y,Ge D.Interleukin-17 promotes migration and invasion of human cancer cells through upregulation of MTA1 expression.Front Oncol2019;9:546 PMCID:PMC6596356

[88] Kryczek I,Nagarsheth N.IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L.Immunity2014;40:772-84 PMCID:PMC4032366

[89] Khosravi N,Cumpian AM.IL22 promotes Kras-mutant lung cancer by induction of a protumor immune response and protection of stemness properties.Cancer Immunol Res2018;6:788-97 PMCID:PMC6030457

[90] Landsberg J,Renn M.Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.Nature2012;490:412-6

[91] Bertrand F,Marcheteau E.TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.Nat Commun2017;8:2256 PMCID:PMC5741628

[92] Chen L,Qin FX.The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression.Oncoimmunology2015;4:e1002731 PMCID:PMC4485725

[93] Müller-Hermelink N,Pichler B.TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis.Cancer Cell2008;13:507-18

[94] Schürch C,Matter MS,Ochsenbein AF.CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression.J Clin Invest2012;122:624-38 PMCID:PMC3266773

[95] Min H,Yang X.Exosomes derived from irradiated esophageal carcinoma-infiltrating T cells promote metastasis by inducing the epithelial-mesenchymal transition in esophageal cancer cells.Pathol Oncol Res2018;24:11-8

[96] Goebel L,Gorys A.CD4⁺ T cells potently induce epithelial-mesenchymal-transition in premalignant and malignant pancreatic ductal epithelial cells-novel implications of CD4⁺ T cells in pancreatic cancer development.Oncoimmunology2015;4:e1000083 PMCID:PMC4485733

[97] Aspord C,Gallegos M.Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development.J Exp Med2007;204:1037-47 PMCID:PMC2118566

[98] Schürch C,Amrein MA.Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ.J Exp Med2013;210:605-21 PMCID:PMC3600910

[99] Sanchez-Perez L,Diaz RM.Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.Cancer Res2005;65:2009-17

[100] Sosa MS,Aguirre-Ghiso JA.Mechanisms of disseminated cancer cell dormancy: an awakening field.Nat Rev Cancer2014;14:611-22 PMCID:PMC4230700

[101] Ochi A,Bedrosian AS.MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells.J Exp Med2012;209:1671-87 PMCID:PMC3428946

[102] McAllister F,Alsina J.Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia.Cancer Cell2014;25:621-37 PMCID:PMC4072043

[103] Arasanz H,Bocanegra A.Early detection of hyperprogressive disease in non-small cell lung cancer by monitoring of systemic T cell dynamics.Cancers (Basel)2020;12:344 PMCID:PMC7073153

[104] Thibult ML,Gertner-Dardenne J.PD-1 is a novel regulator of human B-cell activation.Int Immunol2013;25:129-37

[105] Damsky W,Turner N.B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors.J Immunother Cancer2019;7:153 PMCID:PMC6567557

[106] Zhao KL,Jin HZ,Hu JL.Double-edge role of B cells in tumor immunity: potential molecular mechanism.Curr Med Sci2019;39:685-9

[107] Wang H,Zhao C.An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy.J Immunother Cancer2020;8:e000661 PMCID:PMC7443307

[108] Karagiannis P,Josephs DH.IgG4 subclass antibodies impair antitumor immunity in melanoma.J Clin Invest2013;123:1457-74 PMCID:PMC3613918

[109] Andreu P,Affara NI.FcRgamma activation regulates inflammation-associated squamous carcinogenesis.Cancer Cell2010;17:121-34 PMCID:PMC3082507

[110] Kim SR,Kim JR.The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.BMC Cancer2021;21:19 PMCID:PMC7786505

[111] Lo Russo G,Sommariva M.Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade.Clin Cancer Res2019;25:989-99

[112] Costantini A,Corny J.Nivolumab-refractory patients with advanced non-small-cell lung cancer.Lung Cancer2019;130:128-34

[113] Matsuo N,Kojima T.Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy.Invest New Drugs2021;39:1150-8

[114] Schuiveling M,Verheijden RJ.Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma.Cancer Immunol Immunother2021;70:1491-6 PMCID:PMC8053186

[115] Hagi T,Kawabata R.Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer.Br J Cancer2020;123:965-72 PMCID:PMC7492241

[116] Kim CG,Yoon SE.Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.J Hepatol2021;74:350-9

[117] Hwang I,Yoon SK.Hyperprogressive disease in patients with urothelial carcinoma or renal cell carcinoma treated with PD-1/PD-L1 inhibitors.Clin Genitourin Cancer2020;18:e122-33

[118] Rodriguez Freixinos V,Fasani R.Immune profile and outcomes of patients (pts) with gynecological malignancies (GYN) enrolled in early phases immunotherapy (IO) trials.JCO2018;36:5595

[119] Chiba Y,Yamasaki K,Matsuyama A.Hyper-progressive disease after immune checkpoint inhibitor in SMARCA4-deficient small-cell lung carcinoma.Respirol Case Rep2020;8:e00667 PMCID:PMC7506996

[120] Fricke J,Pharaon R,Rajurkar S.Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: a case report.Medicine (Baltimore)2020;99:e22323 PMCID:PMC7668523

[121] Martorana F,Pavone G.Early gastrointestinal progression to immunotherapy in lung cancer: a report of two cases.Case Rep Oncol Med2021;2021:6692538 PMCID:PMC7939738

[122] Lin Z,Wei Q,Chen X.Hyperprogressive disease in advanced cancer patients with liver metastasis treated with PD-1 inhibitors: two case reports.Ann Transl Med2020;8:1100 PMCID:PMC7575996

[123] Oguri T,Seki S.A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation.Respir Med Case Rep2021;33:101405 PMCID:PMC8042444

[124] Wang W,Liu M.Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication.J Immunother Cancer2020;8:e000793 PMCID:PMC7312344

[125] Huang LT,Zhang SL.Durable clinical response to pyrotinib after resistance to prior anti-HER2 therapy for HER2-positive advanced gastric cancer: a case report.Front Oncol2019;9:1453 PMCID:PMC6951398

[126] Singh B,Maroules M.Hyperprogression in a patient with hepatocellular cancer treated with atezolizumab and bevacizumab: a case report and review of literature.J Investig Med High Impact Case Rep2021;9:2324709621992207 PMCID:PMC8020406

[127] Wong DJ,Choo SP,Hennedige T.Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series.Immunotherapy2019;11:167-75

[128] Chan KH,Ramahi A.Hyperprogressive disease in an advanced stage colon cancer patient on pembrolizumab: a case report.Cureus2020;12:e7764 PMCID:PMC7243062

[129] Yilmaz M.Hyperprogression after nivolumab for melanoma: a case report.J Oncol Pharm Pract2020;26:244-51

[130] Forschner A,Möller Y.Genomics of immunotherapy-associated hyperprogressors-letter.Clin Cancer Res2017;23:6374-5

[131] Koukourakis IM,Koukourakis MI.Radio-immunotherapy: a case report of ‘abscopal hyper-progression’?.Cureus2020;12:e10117 PMCID:PMC7456632

[132] Grecea M,Ammari S,Champiat S.Managing hyperprogressive disease in the era of programmed cell death protein 1/programmed death-ligand 1 blockade: a case discussion and review of the literature.Oncologist2020;25:369-74 PMCID:PMC7216449

[133] Ikushima H,Ohara S.Cisplatin plus pemetrexed therapy and subsequent immune checkpoint inhibitor administration for malignant peritoneal mesothelioma without pleural lesions: case report.Medicine (Baltimore)2020;99:e19956

[134] Xiang JJ,Minja FJ,Burtness BA.Hyperprogression after one dose of nivolumab in sinonasal cancer: a case report.Laryngoscope2020;130:907-10

[135] Chan AS,Snider J,Miller KD.Hyperprogression of liver metastasis with neoadjuvant immunotherapy for soft tissue sarcoma.Cureus2020;12:e8575 PMCID:PMC7358953

[136] Pandiyan P,Ishihara S,Lenardo MJ.CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells.Nat Immunol2007;8:1353-62

[137] Morris AB,Pinelli DF.Signaling through the inhibitory Fc receptor FcγRIIB induces CD8⁺ T cell apoptosis to limit T cell immunity.Immunity2020;52:136-50.e6 PMCID:PMC7326381